Response-based molecular subtyping-emergence of the third generation of breast cancer subtypes

Article Oncology

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Denise M. Wolf et al.

Summary: By incorporating gene expression, protein/phosphoprotein, and clinical data, we have created new breast cancer subtypes that can better predict drug responses. The best performing subtypes include Immune, DNA repair, and HER2/Luminal phenotypes. Treatment allocation based on these subtypes significantly increases the overall pathologic complete response rate. This study is important for guiding future breast cancer treatment.

CANCER CELL (2022)

Add to Collection

Article Oncology

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group

Torsten O. Nielsen et al.

Summary: Ki67 immunohistochemistry (IHC) is commonly used in breast cancer as a proliferation marker, but its analytical validity has been questioned. The International Ki67 in Breast Cancer Working Group (IKWG) recommends careful preanalytical handling, adoption of a standardized visual scoring method, and participation in quality assurance and quality control programs. Clinical utility of Ki67 IHC in breast cancer care is currently limited to prognosis assessment in stage I or II breast cancer.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Add to Collection

Article Oncology

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Lajos Pusztai et al.

Summary: The combination of PD-L1 inhibitor durvalumab and PARP inhibitor olaparib with standard paclitaxel neoadjuvant chemotherapy showed superior efficacy in treating HER2-negative breast cancer, especially in a subset of high-risk HR-positive/HER2-negative patients.

CANCER CELL (2021)

Add to Collection

Article Oncology

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

Carsten Denkert et al.

Summary: The development of anti-HER2 antibody-drug conjugates provides new therapeutic options for breast cancer patients, including those with low expression of HER2. HER2-low-positive breast cancer is a distinct subtype with specific biology, showing differences in response to therapy and prognosis, especially in hormone receptor-negative tumors.

LANCET ONCOLOGY (2021)

Add to Collection

Review Oncology